![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | SKA2 | Human | 17beta-estradiol | increases expression | ISO | Ska2 (Rattus norvegicus) | 6480464 | Estradiol results in increased expression of SKA2 mRNA | CTD | PMID:32145629 | SKA2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Ska2 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of SKA2 mRNA | CTD | PMID:33387578 | SKA2 | Human | 2-hydroxypropanoic acid | affects expression | EXP | | 6480464 | Lactic Acid affects the expression of SKA2 mRNA | CTD | PMID:30851411 | SKA2 | Human | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SKA2 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of SKA2 mRNA | CTD | PMID:28628672 | SKA2 | Human | 4,4'-sulfonyldiphenol | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of SKA2 mRNA | CTD | PMID:28628672 | SKA2 | Human | 4-hydroxyphenyl retinamide | increases expression | ISO | Ska2 (Mus musculus) | 6480464 | Fenretinide results in increased expression of SKA2 mRNA | CTD | PMID:28973697 | SKA2 | Human | 6-propyl-2-thiouracil | increases expression | ISO | Ska2 (Rattus norvegicus) | 6480464 | Propylthiouracil results in increased expression of SKA2 mRNA | CTD | PMID:24780913 | SKA2 | Human | acetamide | increases expression | ISO | Ska2 (Rattus norvegicus) | 6480464 | acetamide results in increased expression of SKA2 mRNA | CTD | PMID:31881176 | SKA2 | Human | aflatoxin M1 | decreases expression | EXP | | 6480464 | Aflatoxin M1 results in decreased expression of SKA2 mRNA | CTD | PMID:30928695 | SKA2 | Human | all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of SKA2 mRNA | CTD | PMID:33167477 | SKA2 | Human | antirheumatic drug | increases expression | EXP | | 6480464 | Antirheumatic Agents results in increased expression of SKA2 mRNA | CTD | PMID:24449571 | SKA2 | Human | arsenite(3-) | multiple interactions | EXP | | 6480464 | arsenite promotes the reaction [G3BP1 protein binds to SKA2 mRNA] | CTD | PMID:32406909 | SKA2 | Human | benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of SKA2 mRNA | CTD | PMID:20064835 | SKA2 | Human | benzo[a]pyrene | increases methylation | EXP | | 6480464 | Benzo(a)pyrene results in increased methylation of SKA2 3' UTR | CTD | PMID:27901495 | SKA2 | Human | benzo[a]pyrene | decreases expression | ISO | Ska2 (Mus musculus) | 6480464 | Benzo(a)pyrene results in decreased expression of SKA2 mRNA | CTD | PMID:19770486 | SKA2 | Human | bisphenol A | increases expression | ISO | Ska2 (Rattus norvegicus) | 6480464 | bisphenol A results in increased expression of SKA2 mRNA | CTD | PMID:25181051 and PMID:32145629 | SKA2 | Human | bisphenol A | decreases expression | ISO | Ska2 (Rattus norvegicus) | 6480464 | bisphenol A results in decreased expression of SKA2 mRNA | CTD | PMID:34947998 | SKA2 | Human | bisphenol F | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SKA2 mRNA | CTD | PMID:28628672 | SKA2 | Human | cadmium atom | multiple interactions | EXP | | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of SKA2 mRNA | CTD | PMID:35301059 | SKA2 | Human | cadmium dichloride | multiple interactions | EXP | | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of SKA2 mRNA | CTD | PMID:35301059 | SKA2 | Human | calcitriol | multiple interactions | EXP | | 6480464 | [Testosterone co-treated with Calcitriol] results in decreased expression of SKA2 mRNA | CTD | PMID:21592394 | SKA2 | Human | calcitriol | decreases expression | EXP | | 6480464 | Calcitriol results in decreased expression of SKA2 mRNA | CTD | PMID:21592394 | SKA2 | Human | carbamazepine | affects expression | EXP | | 6480464 | Carbamazepine affects the expression of SKA2 mRNA | CTD | PMID:25979313 | SKA2 | Human | CGP 52608 | multiple interactions | EXP | | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to SKA2 gene] | CTD | PMID:28238834 | SKA2 | Human | chlordecone | increases expression | ISO | Ska2 (Mus musculus) | 6480464 | Chlordecone results in increased expression of SKA2 mRNA | CTD | PMID:29980752 | SKA2 | Human | cisplatin | increases expression | EXP | | 6480464 | Cisplatin results in increased expression of SKA2 mRNA | CTD | PMID:27594783 | SKA2 | Human | cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of SKA2 mRNA | CTD | PMID:27392435 | SKA2 | Human | cobalt dichloride | decreases expression | EXP | | 6480464 | cobaltous chloride results in decreased expression of SKA2 mRNA | CTD | PMID:19320972 | SKA2 | Human | copper atom | multiple interactions | EXP | | 6480464 | [NSC 689534 binds to Copper] which results in decreased expression of SKA2 mRNA | CTD | PMID:20971185 | SKA2 | Human | copper atom | increases expression | ISO | Ska2 (Rattus norvegicus) | 6480464 | Copper results in increased expression of SKA2 mRNA | CTD | PMID:30556269 | SKA2 | Human | copper(0) | multiple interactions | EXP | | 6480464 | [NSC 689534 binds to Copper] which results in decreased expression of SKA2 mRNA | CTD | PMID:20971185 | SKA2 | Human | copper(0) | increases expression | ISO | Ska2 (Rattus norvegicus) | 6480464 | Copper results in increased expression of SKA2 mRNA | CTD | PMID:30556269 | SKA2 | Human | coumestrol | multiple interactions | EXP | | 6480464 | [Coumestrol co-treated with 2 more ... | CTD | PMID:19167446 | SKA2 | Human | coumestrol | increases expression | EXP | | 6480464 | Coumestrol results in increased expression of SKA2 mRNA | CTD | PMID:19167446 | SKA2 | Human | crocidolite asbestos | decreases expression | ISO | Ska2 (Mus musculus) | 6480464 | Asbestos and Crocidolite results in decreased expression of SKA2 mRNA | CTD | PMID:29279043 | SKA2 | Human | Cuprizon | increases expression | ISO | Ska2 (Rattus norvegicus) | 6480464 | Cuprizone results in increased expression of SKA2 mRNA | CTD | PMID:26577399 | SKA2 | Human | cyclosporin A | decreases expression | EXP | | 6480464 | Cyclosporine results in decreased expression of SKA2 mRNA | CTD | PMID:20106945 more ... | SKA2 | Human | DDE | increases expression | EXP | | 6480464 | Dichlorodiphenyl Dichloroethylene results in increased expression of SKA2 mRNA | CTD | PMID:38568856 | SKA2 | Human | decabromodiphenyl ether | increases expression | ISO | Ska2 (Rattus norvegicus) | 6480464 | decabromobiphenyl ether results in increased expression of SKA2 mRNA | CTD | PMID:23914054 | SKA2 | Human | dexamethasone | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SKA2 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of SKA2 mRNA | CTD | PMID:28628672 | SKA2 | Human | Dibutyl phosphate | affects expression | EXP | | 6480464 | di-n-butylphosphoric acid affects the expression of SKA2 mRNA | CTD | PMID:37042841 | SKA2 | Human | dorsomorphin | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SKA2 mRNA | CTD | PMID:27188386 | SKA2 | Human | doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of SKA2 mRNA | CTD | PMID:29803840 | SKA2 | Human | endosulfan | decreases expression | ISO | Ska2 (Rattus norvegicus) | 6480464 | Endosulfan results in decreased expression of SKA2 mRNA | CTD | PMID:29391264 | SKA2 | Human | Enterolactone | multiple interactions | EXP | | 6480464 | [Coumestrol co-treated with 2 and 3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SKA2 mRNA | CTD | PMID:19167446 | SKA2 | Human | epoxiconazole | decreases expression | ISO | Ska2 (Mus musculus) | 6480464 | epoxiconazole results in decreased expression of SKA2 mRNA | CTD | PMID:35436446 | SKA2 | Human | ethanol | affects splicing | ISO | Ska2 (Mus musculus) | 6480464 | Ethanol affects the splicing of SKA2 mRNA | CTD | PMID:30319688 | SKA2 | Human | FR900359 | increases phosphorylation | EXP | | 6480464 | FR900359 results in increased phosphorylation of SKA2 protein | CTD | PMID:37730182 | SKA2 | Human | indometacin | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SKA2 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of SKA2 mRNA | CTD | PMID:28628672 | SKA2 | Human | lead(0) | affects splicing | EXP | | 6480464 | Lead affects the splicing of SKA2 mRNA | CTD | PMID:28903495 | SKA2 | Human | methotrexate | decreases expression | EXP | | 6480464 | Methotrexate results in decreased expression of SKA2 mRNA | CTD | PMID:17400583 and PMID:24657277 | SKA2 | Human | methylparaben | decreases expression | EXP | | 6480464 | methylparaben results in decreased expression of SKA2 mRNA | CTD | PMID:31745603 | SKA2 | Human | N(4)-hydroxycytidine | decreases expression | ISO | Ska2 (Mus musculus) | 6480464 | N(4)-hydroxycytidine results in decreased expression of SKA2 mRNA | CTD | PMID:37748715 | SKA2 | Human | N-Nitrosopyrrolidine | decreases expression | EXP | | 6480464 | N-Nitrosopyrrolidine results in decreased expression of SKA2 mRNA | CTD | PMID:32234424 | SKA2 | Human | ochratoxin A | increases expression | ISO | Ska2 (Rattus norvegicus) | 6480464 | ochratoxin A results in increased expression of SKA2 mRNA | CTD | PMID:23358140 and PMID:38301995 | SKA2 | Human | oxaliplatin | multiple interactions | ISO | Ska2 (Rattus norvegicus) | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of SKA2 mRNA | CTD | PMID:25729387 | SKA2 | Human | ozone | multiple interactions | ISO | Ska2 (Mus musculus) | 6480464 | [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in increased expression of SKA2 mRNA | CTD | PMID:34911549 | SKA2 | Human | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of SKA2 mRNA | CTD | PMID:22230336 | SKA2 | Human | paracetamol | decreases expression | ISO | Ska2 (Rattus norvegicus) | 6480464 | Acetaminophen results in decreased expression of SKA2 mRNA | CTD | PMID:33387578 | SKA2 | Human | phenethyl isothiocyanate | decreases expression | EXP | | 6480464 | phenethyl isothiocyanate results in decreased expression of SKA2 mRNA | CTD | PMID:26678675 | SKA2 | Human | rac-lactic acid | affects expression | EXP | | 6480464 | Lactic Acid affects the expression of SKA2 mRNA | CTD | PMID:30851411 | SKA2 | Human | resveratrol | multiple interactions | EXP | | 6480464 | [Coumestrol co-treated with Resveratrol] results in increased expression of SKA2 mRNA and [Plant Extracts co-treated with Resveratrol] results in increased expression of SKA2 mRNA | CTD | PMID:19167446 and PMID:23557933 | SKA2 | Human | SB 431542 | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SKA2 mRNA | CTD | PMID:27188386 | SKA2 | Human | sulforaphane | decreases expression | EXP | | 6480464 | sulforaphane results in decreased expression of SKA2 mRNA | CTD | PMID:31838189 | SKA2 | Human | sunitinib | decreases expression | EXP | | 6480464 | Sunitinib results in decreased expression of SKA2 mRNA | CTD | PMID:31533062 | SKA2 | Human | testosterone | multiple interactions | EXP | | 6480464 | [Testosterone co-treated with Calcitriol] results in decreased expression of SKA2 mRNA | CTD | PMID:21592394 | SKA2 | Human | testosterone | decreases expression | EXP | | 6480464 | Testosterone results in decreased expression of SKA2 mRNA | CTD | PMID:21592394 | SKA2 | Human | thimerosal | increases expression | EXP | | 6480464 | Thimerosal results in increased expression of SKA2 mRNA | CTD | PMID:27188386 | SKA2 | Human | thiram | decreases expression | EXP | | 6480464 | Thiram results in decreased expression of SKA2 mRNA | CTD | PMID:38568856 | SKA2 | Human | titanium dioxide | decreases expression | ISO | Ska2 (Mus musculus) | 6480464 | titanium dioxide results in decreased expression of SKA2 mRNA | CTD | PMID:29264374 | SKA2 | Human | topotecan | multiple interactions | ISO | Ska2 (Rattus norvegicus) | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of SKA2 mRNA | CTD | PMID:25729387 | SKA2 | Human | trichostatin A | decreases expression | EXP | | 6480464 | trichostatin A results in decreased expression of SKA2 mRNA | CTD | PMID:24935251 and PMID:26272509 | SKA2 | Human | trichostatin A | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SKA2 mRNA | CTD | PMID:27188386 | SKA2 | Human | trimellitic anhydride | increases expression | ISO | Ska2 (Mus musculus) | 6480464 | trimellitic anhydride results in increased expression of SKA2 mRNA | CTD | PMID:19042947 | SKA2 | Human | triphenyl phosphate | increases expression | ISO | Ska2 (Rattus norvegicus) | 6480464 | triphenyl phosphate results in increased expression of SKA2 mRNA | CTD | PMID:30589522 | SKA2 | Human | triphenyl phosphate | affects expression | EXP | | 6480464 | triphenyl phosphate affects the expression of SKA2 mRNA | CTD | PMID:37042841 | SKA2 | Human | valproic acid | decreases methylation | EXP | | 6480464 | Valproic Acid results in decreased methylation of SKA2 gene | CTD | PMID:29154799 | SKA2 | Human | valproic acid | decreases expression | EXP | | 6480464 | Valproic Acid results in decreased expression of SKA2 mRNA | CTD | PMID:28001369 | SKA2 | Human | valproic acid | decreases expression | ISO | Ska2 (Mus musculus) | 6480464 | Valproic Acid results in decreased expression of SKA2 mRNA | CTD | PMID:21427059 | SKA2 | Human | vorinostat | increases expression | EXP | | 6480464 | vorinostat results in increased expression of SKA2 mRNA | CTD | PMID:27188386 | |